

The BEconneCTDILD Study

A clinical research study for adults with interstitial lung disease (ILD) associated with connective tissue disease

What happens during the study?

Before any study procedures can be done, you will need to read and sign an Informed Consent Form, which contains information about the study.



The study has 4 parts.

| Screening Period | The study team will collect information about your health and run tests to see if you qualify. | | | |
|---|---|--|--|--|
| Study Treatment Period 52 weeks | You will be placed in a group by chance to receive either the study drug or a placebo. | | | |
| Long-Term Extension Study At least 52 weeks | After you complete the Study Treatment Period, you may be eligible to receive the active study drug (no placebo). | | | |
| Follow-up Period | Otherwise, you will have a final safety Follow-up Visit after your last dose of the study treatment. | | | |

What is the purpose of the BEconneCTD-ILD Study?

The purpose of this study is to understand whether the study treatment can help improve lung function in people who have ILD associated with connective tissue disease. ILD causes scarring (lung fibrosis) that makes it difficult for the lungs to get enough oxygen.



Who can join the study?

To be considered for this study, you must meet these and other criteria:



- · Are 18 years of age or older, and
- Have a diagnosis of rheumatoid arthritis, systemic lupus erythematosus, idiopathic inflammatory myopathy (including polymyositis, dermatomyositis, or antisynthetase syndrome), Sjogren's syndrome, or mixed connective tissue disease, and
- Have ILD that is being treated with medicine now or has been treated with medicine in the past.

What is the study treatment?

You have a 50% chance of getting the active study drug or a placebo. Neither you nor the study doctor and staff will know which one you are getting.



The placebo looks just like the study drug but contains no active medicine. This helps researchers understand the true effects of the study drug.

The study treatment is taken by injection once a week. You will be given instructions and shown how to self-inject. The study team can provide extra training at any time.



While the study drug is approved to treat another disease and is well tolerated, it is not approved for patients with ILD.

What tests will I have?

Some of the health checks and tests you will have at study visits include:



Questionnaires Physical exam





Blood tests



Urine test



Pregnancy test (if applicable)



ECG heart test



Lung function tests



High-resolution CT scan (2 times)

You will not have every test at each visit.

CT = computed tomography; ECG = electrocardiogram.

What else should I know?

If you qualify for the study, you will receive study-related treatment, tests, and doctor visits at no cost to you.

Thank you for considering the BEconneCTD-ILD Study.

Clinical research studies help to improve the way doctors treat and prevent illness. This brochure explains a research study being done to learn more about a potential new treatment for ILD associated with connective tissue disease.

Being in a study is completely voluntary. If you decide to join the study and then change your mind, you can leave at any time. Although your condition may or may not improve during the study, information learned may help others living with ILD associated with connective tissue disease.

If you are interested in learning more, please contact us. We are happy to answer any questions you have.

| | | , | | |
|--|--|---|--|--|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

To speak to a study staff member, call



Scan the code or visit [studywebsite.com].

[PIN: XXXX]